Member Info for Wigwammer

Nearly 300 posts, peter. Obsessive clearly

Sebastien Goudreau was part of a small research team working with a CRO to conduct a trial involving a large number of lupus patients. He will likely have chosen his words carefully. That obsession you have with Tim McCarthy - he seems to have got the better of you.. ATB

Sorry bonneville, but you claimed it was a fact that Avion have not said anything about Lupuzor since 2019. In fact, they have. On multiple occasions. At least you’re getting a few sympathy ticks.. DYOR

But we are not talking about Tim, peter. You appear worryingly obsessed. And as a research scientist with immupharma since 2014, Sebastien Goudreau will have had contact with hundreds of very sick lupus patients during the trial. As stated, he will probably have chosen his words carefully. GLA DYOR etc

Sure bonneville. It seems your extensive research process has missed quite a few. Please DYOR

Dec 2023. Commenting further, Art Deas, CEO of Avion said:

"We continue to be excited by the potential of P140 and we look forward to working closely with ImmuPharma and Simbec-Orion, to develop this potentially life changing treatment for Lupus patients."

June 2023. Commenting further, Art Deas, CEO of Avion said: “The FDA has provided us with comprehensive guidance to commence the Phase 2/3 adaptive clinical trial for P140 (Lupuzor™) and we look forward to continue working closely with ImmuPharma to deliver a successful result for Lupus patients." (June 2023)

March 2023. Commenting further, Art Deas, CEO of Avion said: “We remain committed to our full support of ImmuPharma, and with insights gained from last year's PK study and invaluable guidance from the FDA, we believe we have submitted the most robust clinical protocol for Lupuzor™”

Thank you for conceding bonneville, that Avion have commented on Lupuzor since 2019, contrary to your prior post. Please DYOR GLA

A dentist isn’t typically in a situation of responsibility where his/her words may be taken as offering hope to a large number of very sick people, peter. Immupharma, Lupuzor and associated scientists have been responsible for the treatment of hundreds of very sick people over the course of the trials. So if you find the comment bizarre, I can only assume you are missing an empathy chip. ATB

Avion have never said anything about Lupuzor since 2019. Really? “ Commenting further, Art Deas, CEO of Avion said: “We continue to be excited by the potential of P140 and we look forward to working closely with ImmuPharma and Simbec-Orion, to develop this potentially life changing treatment for Lupus patients." (Dec 2023)

You don’t get it, peter. Evidently you are not someone with much experience of medical research, or those who practice in it. As stated, unusual choice of words for a medical research scientist, unless he genuinely believes it. GLA

Commenting on this announcement, Sébastien Goudreau, CEO of ImmuPharma Biotech, said:"These results are extremely compelling… Patients can be very hopeful, I certainly am!"… This would be a very unusual selection of words for a medical scientist, unless of course he is convinced the data is extremely compelling and the potential to treat patients highly promising. Sub £20m market cap, a lot of cynicism built into this valuation.. GLA DYOR

Agree GG.. Late stage assets, tiny market cap, the update will come when it comes. Patience required.. GLA DYOR etc

Monte - your mistake was to hold on to your shares and ridicule others for doing the same (even though they likely bought at a fraction of your entry price)

Well done with your trade, leas. I sold to the value of my original investment at 140p and let the rest run on a free. Obviously with hindsight I should have sold the lot! Agree - it is unlikely to return to 170p+ given the various dilutions, but a similar market cap is realistic (30p+). I think there was a bit more to the buying interest in Jan/Feb than just ramping - the new research conclusions sound interesting, and it has awoken the market again to the point they have late stage assets and a micro valuation. I have been buying over the last 18 months or so, and got an average below 2p which I’m happy with. Anyway, best of luck with whatever you decide. DYOR IMO etc

Bonneville. If you believe the NDA’s were signed with lollipop ladies then probably best you don’t invest further. With a sub £20m valuation, I’m happy to risk some money on the probability the NDA’s were not signed with lollipop ladies. GLA DYOR etc

Monteacute. I have not mis-read your post. Nearly every post you make features some put down or ridicule of current holders. From memory, you have held the stock for nigh on 20 years. It is quite possible that no one here has held the stock longer or with a larger percentage loss than you. So perhaps the finger of ridicule is best pointed at yourself. I should also add that TM was Chair when the shares reached 180p+, and you could have taken a healthy profit. Best taking an objective look at your own scorecard before judging others. ATB

And monteacute is a shareholder here, so I guess he’s just extremely confused about life… Same old with these types. Shares go down they ridicule anyone but themselves, shares go up they give themselves a pat on the back

Your point was that the website is quiet about Lupuzor, bonnville. Even though Lupuzor is emblazoned all over the website

Straight on to the filter for jackarmy

??? Tim has repeatedly stated what he intends to deliver in 2025 across multiple interviews

??? https://www.immupharma.co.uk/folio/lupuzor-lupus/